However, we remain confident in the potential of inhibiting MAO-B to prevent or treat AD, and we believe it also holds promise for the treatment of Parkinson’s disease and depression, while finding MAO-B inhibitors with minimal natural toxicity and side effects hold significant clinical value. This evidence concerns the gene MAOB and major depressive disorder.